



Auro Laboratories Limited

314, T. V. Industrial Estate, S.K. Ahire Marg,
Worli, Mumbai - 400 030, India
Tel. : + 91 22 6663 5456
Fax : +91 22 6663 5460
E-mail : auro@aurolabs.com
Web : www.aurolabs.com

Reg. Off. / Mfg. Unit :
K-56, M. I. D. C. Tarapur,
Dist. Palghar, Maharashtra - 401506.
CIN No. L33125MH1989PLC051910

Date: November 30, 2017.

To
The Deputy General Manager,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400001.

Reg: Security Code No. 530233:

Sub: Outcome of Board Meeting Held on November 30, 2017.

Dear Sir,

Pursuant to provisions of Regulation 30 & Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its Meeting held today (i.e. Thursday, November 30, 2017) has approved the Unaudited Financial Results for the Quarter / Half year ended September 30, 2017 as recommended by the Audit Committee alongwith the statement of Assets and Liabilities and Limited Review Report by the Statutory Auditors of the Company.

In this regard, we are enclosing herewith:

- Unaudited Financial Results for the Quarter/Half year ended September 30, 2017.
- Limited Review Report received from the Statutory Auditor of the Company.
- Statement of Assets & Liabilities as on September 30, 2017




The Meeting of the Board commenced at 2.00 P.M and concluded at 2.45 P. M. The results will be published in the newspaper pursuant to Regulation 47(1)(b) of SEBI (LODR) Regulations, 2015 in due course.

Kindly take the above on your record.

Thanking You.

Yours faithfully,
For AURO LABORATORIES LIMITED


SIDDHARTHA DEORAH
WHOLE TIME DIRECTOR
(DIN: 00230796)



AURO LABORATORIES LIMITED

CIN NO. :- L33125MH1989PLC051910

Regd. Office : K - 56 M.I.D.C INDUSTRIAL AREA, TARAPUR

BOISAR, DIST. PALGHAR 401506, MAHARASHTRA

Tel.: +91-22-66635456 Fax:+91-22-66635460 Email. auro@aurolabs.com Web: www.aurolabs.com


ANNEXURE - I

PART - I							Rs. In Lakt
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2017							
Sr. No.	Particulars	3 Months ended	Preceding 3 Months ended	Corresponding 3 Months ended in the Previous Year	Half year Ended		Previous Year Ended
		30.09.2017 (Unaudited)	30-06-2017 (Unaudited)	30-09-2016 (Unaudited)	30.09.2017 (Unaudited)	30.09.2016 (Unaudited)	31-03-2017 (Audited)
1	Income from Operations						
	(a) Net Sales/Income from Operations (Net of excise duty)	971.79	752.46	814.75	1,724.25	1,814.86	3,547.47
2	Other Income	13.76	2.64	21.03	16.40	22.10	52.69
3	Total Revenue (1 + 2)	985.55	755.10	835.78	1,740.65	1,836.96	3,600.16
4	Expenses						
	a. Consumption of raw material	634.72	579.35	436.91	1,214.07	1,126.69	2,006.36
	b. Purchase of Stock-in-trade	0.85	-	-	0.85	-	1.31
	c. (Increase) / decrease in Finished Goods stock in trade and work in progress	9.15	(121.17)	138.44	(112.02)	170.77	234.16
	d. Employee benefits expense	56.74	72.32	63.43	129.06	123.66	308.08
	e. Finance Cost	32.93	29.89	40.44	62.82	76.42	107.26
	f. Depreciation and amortisation expenses	23	22.00	20.00	45.00	40.00	86.38
	g. Other Expenses	139.92	128.31	115.05	268.23	229.63	565.01
	Total Expenses (4)	897.31	710.70	814.27	1,608.01	1,767.17	3,308.56
5	Profit / (Loss) before exceptional and extraordinary items and tax (3 ± 4)	88.24	44.40	21.51	132.64	69.79	291.60
6	Exceptional items	-	-	-	-	-	-
7	Profit / (Loss) before extraordinary items and tax (5 ± 6)	88.24	44.40	21.51	132.64	69.79	291.60
8	Extraordinary items	-	-	-	-	-	-
9	Profit / (Loss) before tax (7 ± 8)	88.24	44.40	21.51	132.64	69.79	291.60
10	Tax expense	-	-	-	-	-	-
	(a) Current tax expenses for current year	-	-	-	-	-	-
	(b) MAT credit (where applicable)	-	-	-	-	-	-
	(c) Defferered tax	-	-	-	-	-	151.98
11	Profit / (Loss) for the period from continuing operation (9 ± 10)	88.24	44.40	21.51	132.64	69.79	139.62
12	Profit / (Loss) for discontinuing operations	-	-	-	-	-	-
13	Tax expense of discontinuing operations	-	-	-	-	-	-
14	Profit / (Loss) for discontinuing operation (after tax) (12 ± 13)	88.24	44.40	21.51	132.64	69.79	139.62
15	Other Comprehensive Income	(5.74)	9.43	(5.45)	3.69	(1.14)	(0.94)
16	Total Comprehensive Income for the period (14 ± 15)	82.50	53.83	16.06	136.33	68.65	138.68
17	Paid-up equity share capital (Face value of Rs. 10 each)	623.25	623.25	623.25	623.25	623.25	623.25
17	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year)	-	-	-	-	-	376.71
18	Earnings per share (EPS) (Face Value - Rs. 10 per Equity Shares):						
	(a) Basic	1.42	0.71	0.34	2.13	1.12	2.24
	(L) Diluted	1.42	0.71	0.34	2.13	1.12	2.24
<p>FOR & BEHALF OF BOARD OF DIRECTORS FOR AURO LABORATORIES LIMITED</p> <p></p> <p>SIDDHARTHA DEORAH WHOLE TIME DIRECTOR DIN NO. 00230796</p> <p>Place : Mumbai Date : 30.11.2017</p>							

Auro Laboratories Limited

Statement of Assets and Laibilities (Ind AS)

(Rs. In Lakh)

Particulars	As at	As at
	30.09.2017	31/03/2017
	Unaudited	Audited
A ASSETS		
1. Non-Current Assets		
(a) Property, Plant and Equipment	1,257.78	1300.02
(b) Capital Work -in-Progress	103.25	22.62
(c) Investment Property	-	0.00
(d) Financial Assets		
(i) Investments	3.11	4.16
(ii) Loans	-	-
(iii) Others	-	-
(e) Other non-current assets - Capital Advance	-	-
2. Current assets		
(c) Inventories	185.78	132.58
(b) Financial Assets		
(i) Investments	-	-
(ii) Trade Reveivables	719.31	766.84
(iii) Cash and cash equivalent	241.92	49.77
(iv) Bank balances other than (iii) above	41.06	50.75
(v) Loans	-	-
(vi) Others	437.70	409.87
(c) Other Current Assets	-	-
TOTAL ASSETS	2989.91	2736.60
B EQUITY AND LIABILITIES		
1. Equity		
(a) Equity Share Capital	623.25	623.25
(b) Other Equity	513.04	376.71
2. Liabilities		
(I) Non-Current Liabilities		
(a) Financial Liabilities	725.37	494.97
(i) Other Financial Liabilities	405.00	493.30
(b) Provisions	-	-
(c) Deferred Tax Liabilities (Net)	151.98	151.98
(II) Current Liabilities		
(a) Financial Liabilities	-	-
(i) Trade Payables	502.62	490.15
(b) Other Current Liabilities	26.66	66.15
(c) Provisions	41.99	40.09
(d) Current Tax Liabilities (net)	-	-
TOTAL EQUITY AND LIABILITIES	2989.91	2736.60
<p>FOR & BEHALF OF BOARD OF DIRECTORS FOR AURO LABORATORIES LIMITED</p> <p align="center"></p> <p>SIDDHARTHA DEORAH WHOLE TIME DIRECTOR DIN NO. 00230796</p> <p>Place : Mumbai Date : 30.11.2017</p>		


AURO LABORATORIES LIMITED

Notes:

- 1) The above unaudited financial results for the quarter ended 30th September, 2017 were reviewed by the Audit Committee and thereafter approved at the meeting of the Board of Directors of the Company held on 30th November, 2017.
- 2) The Company had adopted Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder. The date of transition to Ind AS is 1st April, 2017 and accordingly these unaudited financial results have been prepared in accordance with recognition and measurement principles laid down in Ind. AS 34 "Interim Financial Reporting" and the other accounting principles generally accepted in India. The impact of transition had been accounted for in the opening reserves and comparative period figures have been reinstated accordingly.
- 3) The Company has only one segment of activity namely "Pharmaceuticals".
- 4) Limited review has been carried out by the Statutory Auditors of the Company
- 5) Figures of previous period have regrouped / reclassified wherever necessary to facilitate comparison.
- 6) There is a possibility that these quarterly financial results may require adjustment before constituting the Final Ind AS financial statements as on the year ending March 31, 2018 due to changes in financial reporting requirements arising from new or revised standards or interpretations issued by MCA or changes in the use of one or more optional exemptions from full retrospective application as permitted under Ind AS 101.
- 7) The reconciliation of Net Profit reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind. AS for the Quarter / Half year and year ended is as under.

Particulars	Rs. in Lacs			
	for the qtr. ended		for the half year ended	for the year ended
	30.09.2016	30.06.2016	30.09.2016	31.03.2017
Profit / (Loss) under previous GAAP	21.26	50.30	71.56	140.34
Ind. AS adjustment:				
Profit / (Loss) on Investment measure at fair value	0.25	(2.02)	(1.77)	(0.72)
Profit / (Loss) under Indian AS	21.51	48.28	69.79	139.62
Other Comprehensive Income	(5.45)	4.31	(1.14)	(0.94)
Total Comprehensive Income for the period	16.06	52.59	68.65	138.68

FOR & BEHALF OF BOARD OF DIRECTORS
FOR AURO LABORATORIES LIMITED



SIDDHARTHA DEORAH
WHOLE TIME DIRECTOR
DIN NO. 00230796

Place : Mumbai
Date : 30.11.2017



KHURDIA JAIN & CO.
CHARTERED ACCOUNTANTS

To,
The Board of Directors,
Auro Laboratories Limited.

We have reviewed the standalone Ind AS financial results of Auro Laboratories Ltd. ("the company") for the period ended September 30, 2017, attached herewith, being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Financial results for the period ended September 30, 2017 have been prepared on the basis of interim financial statements which are responsibility of the Company's Management. Our responsibility is to issue a report on these financial results based on our review of such interim financial statements.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The financial results for the period September 30, 2017, included in the statements, are based on the previously issued financial results of the company, prepared in accordance with the Accounting Standards specified under section 133 of the Companies Act, 2013 read with relevant Rules issued there under, which are reviewed by M/s. Kothari Jain & Associates Chartered Accountants, whose report dated November 10, 2016 express unmodified opinion on those unaudited standalone financial results. Management has adjusted these results for the differences in the accounting principles adopted by the Company on transition to the Indian Accounting Standard ('IND AS') and presented a reconciliation of profit under IND AS of the corresponding period with the profit reported under previous GAAP, which have been approved by the Company's Board of Directors but have not been subjected to a limited review.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements prepared in accordance with generally accepted accounting standards in India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in term of Regulation




KHURDIA JAIN & CO.
CHARTERED ACCOUNTANTS

33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, including the manner in which it is to be disclosed or that it contains any material misstatement.

For Khurdia Jain & Co.
Chartered Accountants

Sampat



Sampat Khurdia
Partner

Membership No. 33615

Firm Reg. No. 120263W

Place: Mumbai

Date: 30/11/2017